Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
基本信息
- 批准号:10723134
- 负责人:
- 金额:$ 9.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAcademiaAccelerationAffectAge of OnsetAllelesAlzheimer&aposs DiseaseAmyloidAmyloid FibrilsAmyloidosisAmyotrophic Lateral SclerosisAnatomyAnterior eyeball segment structureAqueous HumorBenignBlindnessCell DeathCellsChemicalsClinicComprehensionDataDatabasesDefectDeuteriumDevelopmentDiagnosisDiseaseDrainage procedureEndoplasmic ReticulumExhibitsExtracellular MatrixExtracellular Matrix ProteinsEyeEye diseasesFingerprintFoundationsFunctional disorderFundingGlaucomaGleanGoalsGrantGrowthHigh temperature of physical objectHomeostasisHornsHydrogenIndustryInheritedKnowledgeLeadLengthLiquid substanceMass Spectrum AnalysisMeasuresMedicalMedicineMethodsMissense MutationModalityMolecularMolecular ChaperonesMolecular ConformationMolecular StructureMutagenesisMutationNerve DegenerationNuclear Magnetic ResonanceOpen-Angle GlaucomaOutcomePathogenesisPathogenicityPathway interactionsPatientsPeptidesPhysiologic Intraocular PressurePhysiologyPlayProcessProtein BiochemistryProteinsRelaxationResearch PersonnelRetinaRisk FactorsRoleSamplingStructureSusceptibility GeneTestingTherapeuticTimeTissuesToxic effectTrabecular meshwork structureVariantVertebral columnamyloid formationbiophysical propertiesblindcytotoxiccytotoxicityearly onsetexperimental studygain of functiongenome wide association studyinfancyinsightmultidisciplinarymutantmyocilinnon-Nativenovelnovel therapeuticsolfactomedinpatient populationprecision medicinepressureprotein foldingprotein misfoldingproteostasisrare variantsolid state nuclear magnetic resonancestructural biologysuperoxide dismutase 1symptom treatmenttimeline
项目摘要
Glaucoma, a leading cause of blindness worldwide (70 million patients), is managed medically by treating
the symptom of increased intraocular pressure (IOP), but 10% of patients still go blind. IOP is controlled in the
anterior segment of the eye, which contains the trabecular meshwork (TM) extracellular matrix, the anatomical
pathway for drainage of aqueous humor fluid. The TM tissue is diseased in most forms of glaucoma; loss of
TM homeostasis leads to elevated IOP. Hereditary open angle glaucoma, affecting ~3 million young patients,
is caused by mutations in myocilin, a protein highly expressed in the TM. Since 3/2011, studies funded from
R01EY021205 have changed the paradigm for anti-glaucoma therapeutics by laying the molecular foundation
for approaches that target the disease process, which are now being pursued in academia and industry.
We clarified molecular details of the toxic gain-of-function pathogenic mechanism in which mutant
myocilin accumulates in the endoplasmic reticulum (ER) of TM cells, leading to TM cell death and an
accelerated timeline for vision loss. Studies from R01EY021205 (a) contributed fundamental knowledge of
myocilin structure, (b) discovered a counter-productive interaction between myocilin and the ER-resident
Hsp90 chaperone Grp94, and (c) characterized myocilin misfolding as amyloid. Wild-type and many different
myocilin variants harbor a misfolding propensity; thus, proteostasis issues identified in familial myocilin-
associated glaucoma are likely at play in many more patients.
Amyloid formation by myocilin places glaucoma alongside more well-studied amyloid diseases like
Alzheimer and SOD-1 dependent amyotrophic lateral sclerosis, yet our comprehension of the role of amyloid in
glaucoma is in its infancy. Our current objective is to better understand molecular aspects of myocilin
fibrilization, focused on the relevant olfactomedin (OLF) domain. Our multidisciplinary team will (a) clarify
initiation of aggregation by studying solution structures of wild-type and selected OLF variants, as well as
corresponding multi-length scale dynamics, using hydrogen-deuterium exchange mass spectrometry and
nuclear magnetic resonance (NMR) structure and relaxation methods (Wade Van Horn, Co-I) (b) compare the
end-point structures of selected OLF aggregates to known amyloids by solid state NMR (Anant Paravastu, Co-
I) and evaluate cytotoxicity of intermediate aggregates and (c) evaluate common allele full-length myocilin
variants for experimental hallmarks of pathogenicity. The expected outcome is a better understanding of the
myocilin misfolding process at the molecular level, including molecular determinants of pathogenicity, to enable
novel modalities for studying, diagnosing, and treating myocilin-associated glaucoma. More broadly, continued
structure/dysfunction studies of myocilin will not only contribute to our understanding of glaucoma and its role
in the TM, but will also extend our comprehension of the many other OLF domains, which are implicated
broadly in physiology and diseases.
青光眼是全球失明的主要原因(7,000万患者),通过治疗来管理
眼内压力增加(IOP)的症状,但10%的患者仍然失明。 IOP在
眼睛的前部,其中包含小梁网(TM)细胞外基质,解剖学
流体流体排水的途径。 TM组织以大多数形式的青光眼患病。损失
TM稳态导致IOP升高。遗传性开倾角青年瘤,影响约30万年轻患者,
是由在TM中高度表达的肌动蛋白突变引起的。自3/2011以来,从
R01EY021205通过奠定分子基础改变了抗云可瘤疗法的范例
对于针对疾病过程的方法,该方法现在正在学术界和工业中采用。
我们阐明了有毒功能获得的致病机制的分子细节,其中突变体
肌动蛋白积聚在TM细胞的内质网(ER)中,导致TM细胞死亡和A
加速视力丧失的时间表。 R01EY021205(a)的研究贡献了基本知识
肌动蛋白的结构,(b)发现了肌动蛋白与er-ersentent之间的适得其反相互作用
HSP90伴侣GRP94,(C)将肌动蛋白折叠折叠为淀粉样蛋白。野生型和许多不同的
肌动蛋白变体具有错误折叠的倾向;因此,在家族性肌动蛋白 -
相关的青光眼可能会在更多患者中发挥作用。
肌动蛋白的淀粉样蛋白形成将青光眼与更精心培养的淀粉样蛋白疾病一样
阿尔茨海默氏症和SOD-1依赖性肌萎缩性横向硬化症,但我们对淀粉样蛋白的作用的理解
青光眼仍处于起步阶段。我们目前的目标是更好地了解肌动蛋白的分子方面
纤维化,重点是相关的嗅觉素(OLF)结构域。我们的多学科团队将(a)澄清
通过研究野生型和选定的OLF变体的溶液结构以及
使用氢欧交换质谱法和相应的多长度尺度动力学
核磁共振(NMR)结构和松弛方法(Wade Van Horn,Co-I)(b)比较
固态NMR(Anant Paravastu,co-
i)并评估中间聚集体的细胞毒性和(c)评估普通等位基因全长肌动蛋白
致病性实验标志的变体。预期的结果是对
在分子水平上的肌动蛋白错误折叠过程,包括致病性的分子决定因素,以实现
研究,诊断和治疗肌动蛋白相关的青光眼的新型方式。更广泛地,继续
肌动蛋白的结构/功能障碍研究不仅有助于我们对青光眼及其作用的理解
在TM中,但也将扩展我们对许多其他OLF领域的理解,这与
在生理和疾病方面广泛。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raquel L Lieberman其他文献
Raquel L Lieberman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Raquel L Lieberman', 18)}}的其他基金
Characterization of purified myocilin : glaucoma as a protein misfolding disease DEIA Supplement
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病 DEIA 补充
- 批准号:
10789112 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
8616070 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
10357759 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
9239535 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
10052403 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
8232001 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Request for Supplement to Promote Diversity in Health Related Research
请求补充以促进健康相关研究的多样性
- 批准号:
10359309 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
CHARACTERIZATION OF PURIFIED MYOCILIN: INSIGHT INTO GLAUCOMA
纯化肌青蛋白的表征:洞察青光眼
- 批准号:
10622963 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
8420505 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
Characterization of purified myocilin: glaucoma as a protein misfolding disease
纯化肌纤蛋白的表征:青光眼作为一种蛋白质错误折叠疾病
- 批准号:
10614924 - 财政年份:2011
- 资助金额:
$ 9.97万 - 项目类别:
相似海外基金
Development of Strategies for the Enantioselective Synthesis of Heterocycles and Acyclic Amines
杂环和无环胺对映选择性合成策略的发展
- 批准号:
10656344 - 财政年份:2022
- 资助金额:
$ 9.97万 - 项目类别:
Hyperspectral Single Photon Imaging of Targeted Alpha-Emitters
目标阿尔法发射器的高光谱单光子成像
- 批准号:
10633193 - 财政年份:2021
- 资助金额:
$ 9.97万 - 项目类别:
Scaling Volumetric Imaging, Analysis and Science Communication Using Immersive Virtual Reality
使用沉浸式虚拟现实扩展体积成像、分析和科学传播
- 批准号:
10604786 - 财政年份:2020
- 资助金额:
$ 9.97万 - 项目类别:
Monitoring neoadjuvant chemotherapy of breast cancer using 3D subharmonic aided pressure estimation
使用 3D 分谐波辅助压力估计监测乳腺癌新辅助化疗
- 批准号:
10614640 - 财政年份:2019
- 资助金额:
$ 9.97万 - 项目类别: